Technology Experts Will Soon Earn A Higher Salary Of Archaeology
Quantum technology will be worth trillions of dollars and transform the economy over the next decade. What is it, and how can we build a quantum economy? Innovation thrives on technology convergence, combination, and compounding. Mastering these forces can help tackle global challenges and shape the future of technology. Emerging Technologies Regulation now shapes innovation as much as technology - here's why it's an infrastructure investment
The Technology Convergence Report 2025 offers leaders a strategic lens – the 3C Framework – to help them navigate the combinatorial innovation era. The debate over whether education technology is a critical learning tool or ineffective and detrimental to children’s well-being comes as billions in federal pandemic relief money—the bulk of ... A report by the Center for Democracy and Technology looks at teachers' and students' experiences with the technology. MIT researchers discovered that dendrites, cracks that harm the performance of solid-state batteries, can grow at far lower stresses than previously understood. The findings reveal why developing stronger solid electrolytes alone hasn’t solved the dendrite problem; more chemically stable materials will be needed to finally fulfill the promise of these batteries. From smartphones to social media and healthcare, here's a brief history of the ways in which technology has transformed our lives in the past 20 years. Avectas is a cell engineering technology business focused on improving the cost, manufacturing and patient outcomes for the next generation of cellular therapies. Our vision is to position the non-viral Solupore® cell engineering technology to be integrated into manufacturing processes, including complex gene editing, for multiple autologous and allogeneic therapies and commercialized through development and license agreements.
From smartphones to social media and healthcare, here's a brief history of the ways in which technology has transformed our lives in the past 20 years. Avectas is a cell engineering technology business focused on improving the cost, manufacturing and patient outcomes for the next generation of cellular therapies. Our vision is to position the non-viral Solupore® cell engineering technology to be integrated into manufacturing processes, including complex gene editing, for multiple autologous and allogeneic therapies and commercialized through development and license agreements. “The key difference between our platform and competing technology is the gentleness. Currently, cells that are being modified are typically from a patient who may be ill and the cells may be fragile.
